probucol has been researched along with Glomerulonephritis, IGA in 2 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Glomerulonephritis, IGA: A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated the efficacy and safety of probucol (an anti-oxidant) combined with valsartan (an ARB) on the progression of IgA nephropathy." | 2.79 | Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study. ( Feng, Z; Hou, S; Hu, H; Liang, Y; Shi, W; Shi, X; Wang, L; Wang, W; Xia, Y; Xu, L; Yan, H; Ye, Z; Zhang, B; Zhang, L; Zhong, W, 2014) |
| "Treatment with probucol resulted in the improvement of both hyperlipoproteinemia and proteinuria with the disappearance of the lipoprotein thrombi in the glomerular capillary without any change in the mesangial IgA deposition." | 2.39 | A case of lipoprotein glomerulopathy successfully treated with probucol. ( Amenomori, M; Haneda, M; Hidaka, H; Kikkawa, R; Maeda, S; Morikawa, J; Nishigaki, I; Shigeta, Y, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, Z | 1 |
| Zhang, L | 1 |
| Xu, L | 1 |
| Shi, W | 1 |
| Hu, H | 1 |
| Shi, X | 1 |
| Zhong, W | 1 |
| Hou, S | 1 |
| Yan, H | 1 |
| Zhang, B | 1 |
| Xia, Y | 1 |
| Wang, W | 1 |
| Feng, Z | 1 |
| Wang, L | 1 |
| Liang, Y | 1 |
| Amenomori, M | 1 |
| Haneda, M | 1 |
| Morikawa, J | 1 |
| Nishigaki, I | 1 |
| Maeda, S | 1 |
| Hidaka, H | 1 |
| Kikkawa, R | 1 |
| Shigeta, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy[NCT00426348] | Phase 4 | 75 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for probucol and Glomerulonephritis, IGA
| Article | Year |
|---|---|
A case of lipoprotein glomerulopathy successfully treated with probucol.
Topics: Female; Glomerulonephritis, IGA; Humans; Hyperlipoproteinemia Type III; Kidney Diseases; Lipids; Mid | 1994 |
1 trial available for probucol and Glomerulonephritis, IGA
| Article | Year |
|---|---|
Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antioxidants; Drug Therapy, Combination; Femal | 2014 |